Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors

European Journal of Medicinal Chemistry

Volumn 94, Issue , 2015, Pages 140-148

  Rothweiler, Ulli ^a   Eriksson, Jonas ^b,c   Stensen, Wenche ^a,b   Leeson, Frederick ^a,b   Engh, Richard A ^a   Svendsen, John S ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b LYTIX BIOPHARMA AS   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Crystallography; Drug design; Inhibitor profiling; Luciferin; Protein kinase

Indexed keywords

CASEIN KINASE II; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; LUCIFERIN; PROTEIN KINASE; PROTEIN KINASE DYRK; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; CDK2 PROTEIN, HUMAN; DYRK KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ARTICLE; BIOPROSPECTING; CROSS REACTION; DRUG DESIGN; DRUG DETERMINATION; ENZYME INHIBITION; HYDROGEN BOND; IN VITRO STUDY; OBSERVATIONAL STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; PRECLINICAL STUDY; PROCEDURES; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FIREFLY LUCIFERIN; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84924355836     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.02.035     Document Type: Article

References (33)

1. A. Lundin, J. Eriksson, A real-time bioluminescent HTS method for measuring protein kinase activity influenced neither by ATP concentration nor by luciferase inhibition, Assay Drug Dev. Technol. 6 (2008) 531-541.
2. P. Singh, B.J. Harden, B.J. Lillywhite, P.M. Broad, Identification of kinase inhibitors by an ATP depletion method, Assay Drug Dev. Technol. 2 (2004) 161-169.
3. J. Bain, L. Plater, M. Elliott, N. Shapiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S. Arthur, D.R. Alessi, P. Cohen, The selectivity of protein kinase inhibitors: a further update, Biochem. J. 408 (2007) 297-315.
4. E.H. White, F. McCapra, G.F. Field, The structure and synthesis of firefly luciferin, J. Am. Chem. Soc. 85 (1963) 337-343.
5. D.C. McCutcheon, M.A. Paley, R.C. Steinhardt, J.A. Prescher, Expedient synthesis of electronically modified luciferins for bioluminescence imaging, J. Am. Chem. Soc. 134 (2012) 7604-7607.
6. G. Meroni, M. Rajabi, E. Santaniello, D-Luciferin, derivatives and analogues: synthesis and in vitro/in vivo luciferase-catalyzed bioluminicent activity, ARKIVOC 2009 (2009) 265-288.
7. H.-J. Böhm, S. Brode, U. Hesse, G. Klebe, Oxygen and nitrogen in competitive situations: which is the hydrogen-bond acceptor? Chem. A Eur. J. 2 (1996) 1509-1513.
8. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, J. Massague, N.P. Pavletich, Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex, Nature 376 (1995) 313-320.
9. A.A. Russo, P.D. Jeffrey, A.K. Patten, J. Massague, N.P. Pavletich, Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin ACdk2 complex, Nature 382 (1996) 325-331.
10. R.A. Engh, D. Bossemeyer, The protein kinase activity modulation sites: mechanisms for cellular regulation e targets for therapeutic intervention, Adv. Enzyme Regul. 41 (2001) 121-149.
11. B. Smith, F. Medda, V. Gokhale, T. Dunckley, C. Hulme, Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem. Neurosci. 3 (2012) 857-872.
12. M.A. Beniddir, E. Le Borgne, B.I. Iorga, N. Loaec, O. Lozach, L. Meijer, K. Awang, M. Litaudon, Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors, J. Nat. Prod. 77 (2014) 1117-1122.
13. J. Bain, H. McLauchlan, M. Elliott, P. Cohen, The specificities of protein kinase inhibitors: an update, Biochem. J. 371 (2003) 199-204.
14. M. Gompel, M. Leost, E.B. De Kier Joffe, L. Puricelli, L.H. Franco, J. Palermo, L. Meijer, Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum, Bioorg. Med. Chem. Lett. 14 (2004) 1703-1707.
15. C. Neagoie, E. Vedrenne, F. Buron, J.Y. Merour, S. Rosca, S. Bourg, O. Lozach, L. Meijer, B. Baldeyrou, A. Lansiaux, S. Routier, Synthesis of chromeno[3,4-b] indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class, Eur. J. Med. Chem. 49 (2012) 379-396.
16. M. Debdab, F. Carreaux, S. Renault, M. Soundararajan, O. Fedorov, P. Filippakopoulos, O. Lozach, L. Babault, T. Tahtouh, B. Baratte, Y. Ogawa, M. Hagiwara, A. Eisenreich, U. Rauch, S. Knapp, L. Meijer, J.P. Bazureau, Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing, J. Med. Chem. 54 (2011) 4172-4186.
17. P. Kassis, J. Brzeszcz, V. Beneteau, O. Lozach, L. Meijer, R. Le Guevel, C. Guillouzo, K. Lewinski, S. Bourg, L. Colliandre, S. Routier, J.Y. Merour, Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(phenyl) pyridine or pyrazine V-shaped molecules as kinase inhibitors and cytotoxic agents, Eur. J. Med. Chem. 46 (2011) 5416-5434.
18. Y. Loidreau, P. Marchand, C. Dubouilh-Benard, M.R. Nourrisson, M. Duflos, O. Lozach, N. Loaec, L. Meijer, T. Besson, Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors, Eur. J. Med. Chem. 58 (2012) 171-183.
19. Y. Loidreau, P. Marchand, C. Dubouilh-Benard, M.R. Nourrisson, M. Duflos, N. Loaec, L. Meijer, T. Besson, Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b] thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases, Eur. J. Med. Chem. 59 (2013) 283-295.
20. L. Demange, F.N. Abdellah, O. Lozach, Y. Ferandin, N. Gresh, L. Meijer, H. Galons, Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling, Bioorg. Med. Chem. Lett. 23 (2013) 125-131.
21. E. Deau, Y. Loidreau, P. Marchand, M.R. Nourrisson, N. Loaec, L. Meijer, V. Levacher, T. Besson, Synthesis of novel 7-substituted pyrido[2′,3′:4,5]furo [3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases, Bioorg. Med. Chem. Lett. 23 (2013) 6784-6788.
22. O. Dehbi, A. Tikad, S. Bourg, P. Bonnet, O. Lozach, L. Meijer, M. Aadil, M. Akssira, G. Guillaumet, S. Routier, Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors, Eur. J. Med. Chem. 80 (2014) 352-363.
23. Y. Ogawa, Y. Nonaka, T. Goto, E. Ohnishi, T. Hiramatsu, I. Kii, M. Yoshida, T. Ikura, H. Onogi, H. Shibuya, T. Hosoya, N. Ito, M. Hagiwara, Development of a novel selective inhibitor of the down syndrome-related kinase Dyrk1A, Nat. Commun. 1 (2010) 86.
24. K. Anderson, Y. Chen, Z. Chen, R. Dominique, K. Glenn, Y. He, C. Janson, K.C. Luk, C. Lukacs, A. Polonskaia, Q. Qiao, A. Railkar, P. Rossman, H. Sun, Q. Xiang, M. Vilenchik, P. Wovkulich, X. Zhang, Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors, Bioorg. Med. Chem. Lett. 23 (2013) 6610-6615.
25. M. Soundararajan, A.K. Roos, P. Savitsky, P. Filippakopoulos, A.N. Kettenbach, J.V. Olsen, S.A. Gerber, J. Eswaran, S. Knapp, J.M. Elkins, Structures of down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition, Structure 21 (2013) 986-996.
26. T. Tahtouh, J.M. Elkins, P. Filippakopoulos, M. Soundararajan, G. Burgy, E. Durieu, C. Cochet, R.S. Schmid, D.C. Lo, F. Delhommel, A.E. Oberholzer, L.H. Pearl, F. Carreaux, J.P. Bazureau, S. Knapp, L. Meijer, Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B, J. Med. Chem. 55 (2012) 9312-9330.
27. G. Cozza, L.A. Pinna, S. Moro, Protein kinase CK2 inhibitors: a patent review, Expert Opin. Ther. Pat. 22 (2012) 1081-1097.
28. K. Niefind, M. Putter, B. Guerra, O.G. Issinger, D. Schomburg, GTP plus water mimic ATP in the active site of protein kinase CK2, Nat. Struct. Biol. 6 (1999) 1100-1103.
29. S.L. Bostrom, J. Dore, L.C. Griffith, CaMKII uses GTP as a phosphate donor for both substrate and autophosphorylation, Biochem. Biophys. Res. Commun. 390 (2009) 1154-1159.
30. K. Schinkmann, J. Blenis, Cloning and characterization of a human STE20-like protein kinase with unusual cofactor requirements, J. Biol. Chem. 272 (1997) 28695-28703.
31. M. Gschwendt, W. Kittstein, K. Kielbassa, F. Marks, Protein-kinase C-Delta accepts Gtp for autophosphorylation, Biochem. Biophys. Res. Commun. 206 (1995) 614-620.
32. C.A. Smith, M. Toth, H. Frase, L.J. Byrnes, S.B. Vakulenko, Aminoglycoside 2′- phosphotransferase IIIa (APH(2′)-IIIa) prefers GTP over ATP: structural templates for nucleotide recognition in the bacterial aminoglycoside-2′ kinases, J. Biol. Chem. 287 (2012) 12893-12903.
33. C.J. Hastie, H.J. McLauchlan, P. Cohen, Assay of protein kinases using radiolabeled ATP: a protocol, Nat. Protoc. 1 (2006) 968-971.